tipifarnib has been researched along with 7-hydroxystaurosporine in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (7-hydroxystaurosporine) | Trials (7-hydroxystaurosporine) | Recent Studies (post-2010) (7-hydroxystaurosporine) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 322 | 20 | 51 |
| Protein | Taxonomy | tipifarnib (IC50) | 7-hydroxystaurosporine (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | 0.0099 | |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA | 1 |
1 other study(ies) available for tipifarnib and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays | 2008 |